



HANSA
BIOPHARMA

**Interim Results
Conference Call**

October 17, 2024



Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Interim Results Conference Call Agenda



17 October 2024



CEO Remarks

Søren Tulstrup

Chief Executive Officer, President

Operational Update

Søren Tulstrup

Chief Executive Officer, President

Pipeline Update

Hitto Kaufmann

Chief R&D Officer

Financial Results

Evan Ballantyne


Chief Financial Officer

Q&A and Close

Søren Tulstrup

Chief Executive Officer, President

Highest ever quarterly IDEFIRIX sales performance



Performance Highlights

Q3'24 Sales - IDEFIRIX

- > 69.5 MSEK
- > Net Provision: 39.8 MSEK

YTD Revenue - IDEFIRIX

- > 164.1 MSEK
- > Net Provision: 114.5 MSEK

Q3 Provision - 29.7 MSEK

- > Accounts for ongoing price negotiations and repayment

Significant scientific advancement in 2024

Key Trial Progress

**ConfIdeS Ph 3
(kidney transplant)**

Enrolment complete
data read out 2H 2025

**PAES Ph 3
(kidney transplant)**

78% enrolled
data read out 2025

**GOOD-IDES-02 Ph 3
(anti-GBM)**

86% enrolled
data read out 2025

Publications & Presentations

**17-HMedIdes-14
(kidney transplant)**

Presented at AST
meeting (June)

**16-HMedIdes-12 Ph 2
(AMR)**

Published in *Clinical
Transplantation*
(July)

**RWE Data
(kidney transplant)**

Published in *KI Report* (July)
Presented at AST meeting
(June)

IDEFIRIX EU launch continues to advance



Clinical Readiness

113 clinics are IDEFIRIX ready to treat

32 centers with clinical experience
10% increase from Q2

62% of clinics in 11 markets have repeat use

53 patients identified in countries with ET program



Patient Selection & Treatment

123 local scientific events and KOL engagement

7 countries issued clinical guidelines



Market Access

Reimbursement in 15 markets incl largest EU markets

Access in 75% of EU transplant market

Interim Results Conference

17 October 2024



CEO Remarks

Søren Tulstrup

Chief Executive Officer, President

Operational Update

Søren Tulstrup

Chief Executive Officer, President

Pipeline Update

Hitto Kaufmann

Chief R&D Officer

Financial Results

Evan Ballantyne

Chief Financial Officer

Q&A and Close

Søren Tulstrup

Chief Executive Officer, President

Broad pipeline in autoimmune, gene therapy and transplantation

	Preclinical	Phase 1	Phase 2	Phase 3	Marketing authorization	Marketed	Partner	Status	Next anticipated milestone
Imlifidase									
EU: Kidney transplantation in highly sensitized patients ^{1,2}								Commercialization ongoing ● Post approval Clinical Phase 3 ongoing	EU: Additional agreements around reimbursement / Post authorization study to be completed in 2025
U.S. "ConfideS": Kidney transplantation in highly sensitized patients ^{1,2}								Clinical Phase 3 ongoing	Data readout in 2H 2025
GOOD-IDE S-02: Anti-GBM antibody disease								Clinical Phase 3 ongoing	Complete enrolment (50 patients)
16-HMedldeS-12: Active Antibody Mediated Rejection (AMR)								Clinical Phase 2 completed	Publication in peer-reviewed journal
15-HMedldeS-09: Guillain-Barré Syndrome (GBS)								Clinical Phase 2 ongoing	Comparative efficacy analysis 2024
Investigator-initiated trial in ANCA-associated vasculitis ³								Clinical Phase 2 ongoing	Complete enrolment (10 patients)
SRP-9001-104: Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (DMD)								Clinical Phase 1b ongoing	Complete enrolment
Pre-treatment ahead of gene therapy in Limb-Girdle Muscular Dystrophy (LGMD)								Preclinical research ongoing	Preclinical research
Pre-treatment ahead of gene therapy in Pompe disease								Preclinical research ongoing	Preclinical research
Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome								Preclinical research ongoing	Commence clinical study
HNSA-5487									
NICE-01: HNSA-5487 – Lead candidate from the NiceR program								Clinical Phase 1 completed	Alignment with regulatory authorities on development path

¹ Results from the Phase 1 study have been published: Winstock et al. (2015) PLOS ONE 10(7)
² Lazar et al., American Journal of Transplantation and 0-3404 studies (Jordan et al., New England Journal of Medicine)
³ Investigator-initiated study by Dr. Adnan Scharf and Dr. Philipp Engelhardt at Charité University Medicine, Berlin, Germany

Advancing the science in autoimmune, gene therapy, and transplantation

Delivering the Pipeline

- 7 Ongoing clinical trials in autoimmune, gene therapy and transplantation
- 1 Additional gene therapy study to commence in 2024

Advancing the Science

- 7 Publications in peer-reviewed journal
- 8 Presentations at leading medical congresses



IMLIFIDASE IgG cleaving therapy with a unique MOA

AUTOIMMUNE

15-HMedIdeS-09 Ph 2 (GBS)
Trial Complete
Add'l Data Readout Q4 2024

GOOD-IDES-02 Ph 3 (anti-GBM disease)
Ongoing
Data Readout 2H 2025

GENE THERAPY

SRP-9001-104 Ph 1b (DMD)
Trial Commenced
Data Readout 2025

Genethon Preclinical (Crigler-Najjar)
Trial to Commence Q4 2024

AskBio Preclinical (Pompe disease)
Trial to Commence 2025

TRANSPLANTATION

US ConfideS Ph 3 (kidney)
Enrolment Completed
Data Readout 2H 2025

16-HMedIdeS-12 Ph 2 (AMR)
Trial Complete
Data published July 2024

Post Authorization Efficacy Ph 3 (kidney)
Ongoing
Data readout 2025

HNSA-5487 next-gen IgG cleaving molecule with redosing potential

NICE-01 Ph 1
Trial Complete
Additional Analysis Complete
Clinical Development Path Annc

HNSA-5487 has the potential to address high unmet medical need in IgG mediated diseases

HNSA-5487

- ✓ Clear redosing potential with optimized IgG reduction
- ✓ Demonstrated rapid, robust reduction of IgG by 95% after single dose
- ✓ Favorable safety and tolerability profile

Neuromyelitis Optica (NMO)

The body's immune system mistakenly attacks healthy cells and proteins in the body, most often those in the spinal cord and eyes.¹


Myasthenia Gravis (MG)

A rare, chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups.^{2,3}

MOGAD

Inflammatory disorder of the central nervous system characterized by attacks of immune-mediated demyelination predominantly targeting the optic nerves, brain, and spinal cord.⁴

IgG-mediated neuro-autoimmune diseases



1. Briggs FB, Shaia J. Prevalence of neuromyelitis optica spectrum disorder in the United States. *Multiple Sclerosis Journal*. 2024;30(3):316324. doi:10.1177/13524595231224683

2. Panga A, Maddison P, Heckmann J, et al. Epidemiology, diagnosis, and biomarkers of autoimmune neuromuscular junction disorders. *Lancet Neurol* 2022; 21: 176–186.

3. Schneider-Gold, Christiane, and Nils Erik Gilhus. "Advances and challenges in the treatment of myasthenia gravis." *Therapeutic advances in neurological disorders* vol. 14 17562864211065406. 21 Dec 2021. doi:10.1177/17562864211065406

4. MOGAD Disorder and Multiple Sclerosis: Understanding Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). National MS Society. March 2023. <https://www.nationalmssociety.org/understanding-ms/what-is-ms/related-conditions/mogad>. Accessed 17 September 2024.

Interim Results Conference

17 October 2024



CEO Remarks

Søren Tulstrup

Chief Executive Officer, President

Operational Update

Søren Tulstrup

Chief Executive Officer, President

Pipeline Update

Hitto Kaufmann

Chief R&D Officer

Financial Results

Evan Ballantyne





Chief Financial Officer

Q&A and Close

Søren Tulstrup

Chief Executive Officer, President


Highest ever quarterly IDEFIRIX sales performance totalling 69.5 MSEK offset by 29.7 MSEK provision



*From agreements with Sarepta, AskBio & Axis-Shield

Continued investments in R&D and commercialization


SG&A expenses (Q/Q)




R&D expenses (Q/Q)




Operating loss (Q/Q)




SG&A expenses (9M/9M)



R&D expenses (9M/9M)




Operating loss (9M/9M)




Cash runway into 2026 through directed share issue in Q2'24


Operating cash flow (Q/Q)




Operating cash flow (9M/9M)



Cash & Cash Equivalents (Q/Q)



Number of employees (Q/Q)



Interim Results Conference

17 October 2024



CEO Remarks

Søren Tulstrup

Chief Executive Officer, President

Operational Update

Matt Shaulis

Chief Commercial Officer

Pipeline Update

Hitto Kaufmann

Chief R&D Officer

Financial Results

Evan Ballantyne

Chief Financial Officer

Q&A and Close

Søren Tulstrup

Chief Executive Officer, President

HANSA BIOPHARMA LEADERSHIP



Søren Tulstrup
President & CEO



Hitto Kaufmann
Chief R&D Officer



Evan Ballantyne
CFO

Hansa Biopharma contacts and key events

Contacts



Evan Ballantyne

Chief Financial Officer

Email: ir@hansabiopharma.com



Stephanie Kenney

VP, Corporate Affairs

E-mail: media@hansabiopharma.com

Calendar and events

2024

- 7 SEPT Truist Securities BioPharma Symposium, NYC
- 19 NOV Jefferies Global Healthcare Conference, London
- 3 DEC Piper Sandler 36th Annual Healthcare Conference, NYC

2025

- 6 FEB Full-year 2024 (January – December) Report
- 21 MAR Annual & Sustainability Report 2024
- 17 APR Q1 2025 (January – March) Report
- 17 JULY Q2 2025 (January – June) Report



HANSA®

BIOPHARMA